4DMT reports FY22 net loss of $107.5M; cash runway into H1 2025; pipeline advances

4D Molecular Therapeutics, Inc.

Net loss $107.5M in 2022 (vs $71.3M in 2021); revenue $3.1M (vs $18.0M) due to Roche collaboration end.
Cash, equivalents & marketable securities $218.5M; expected to fund operations into first half 2025.
4D-150 wet AMD interim data: >90% reduction in anti-VEGF injections; dose exploration enrolled, phase 2 dose expansion started Jan 2023. DME IND cleared.
4D-710 cystic fibrosis: cohort 2 enrollment completed Feb 2023; interim data planned for Q2 2023 conference.
4D-310 Fabry cardiomyopathy: interim cardiac improvements shown; FDA clinical hold response expected Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

4D Molecular Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $3.1 million.

Period: the year ended December 31, 2022
Revenue: $3.1 million
Result: reported results

Exact text from the filing

Total revenue was $3.1 million for 2022, as compared to $18.0 million for 2021.

View on SEC.gov

Browse all earnings releases →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.